Merck

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer

Retrieved on: 
Monday, October 18, 2021
MSD, Royal commission, HIV disease progression rates, Death, Merck, Eisai, Cancer, Risk, Radiation, RCC, Adult, European Medicines Agency, Merck & Co., Committee for Medicinal Products for Human Use, Committee, PFS, Patient, Progression-free survival, European Union, European Commission, CHMP, EC, Union, Pharmaceutical industry

"KEYTRUDA plus LENVIMA demonstrated a survival benefit for advanced renal cell carcinoma in the first-line setting and represents an important potential new treatment option for these patients.

Key Points: 
  • "KEYTRUDA plus LENVIMA demonstrated a survival benefit for advanced renal cell carcinoma in the first-line setting and represents an important potential new treatment option for these patients.
  • "We are pleased that the CHMP has recognized the important role of the combination therapy in these difficult-to-treat cancers."
  • Renal cell carcinoma is by far the most common type of kidney cancer; about nine out of 10 kidney cancer diagnoses are RCC.
  • (7) American Cancer Society, Facts & Figures 2020 pdf:
    (8) International Agency for Research on Cancer, World Health Organization.

Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

Retrieved on: 
Friday, October 15, 2021
Patient, Infection, Pneumonia, Merck, American College, Private Securities Litigation Reform Act, Hercules, Awareness, LEAP, Growth, Bronchopneumonia, FCCP, Tablet, SEC, MS, Physician, Fosfomycin, American College of Chest Physicians, Cutis marmorata telangiectatica congenita, Food and Drug Administration, GLOBE, Food, Urinary tract infection, Pyelonephritis, MD, NASDAQ, Therapy, COVID-19, Pharmaceutical industry, Vaccine

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.

Key Points: 
  • DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Global Antibiotics Markets, Share & Trends Analysis 2021-2028 by Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Health, Pharmaceutical, World, Government, Peptide, Merck, Shanda, World Health Organization, Lincosamides, Awareness, European Investment Bank, Cephalosporin, The Pew Charitable Trusts, Tetracycline, Relebactam, Infection, USD, New Drug Application, Patient, Takeda Pharmaceutical Company, Trust law, Ceftobiprole, Wellcome Trust, Review, Medication, Prescription, Research, Pew, R, Fine chemical, Pharmaceutical industry, Antibiotics

High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market.

Key Points: 
  • High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market.
  • An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline.
  • For instance, in December 2018, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.
  • Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period.

(XLRN): Johnson Fistel Investigates Proposed Sale of Acceleron Pharma; Is $180 a Fair Price?

Retrieved on: 
Friday, October 15, 2021
Learning, LLP, XLRN, Sale, Merck & Co., Merck, NASDAQ, Acquisition, Company, Pharmaceutical industry

Under the agreement terms, Acceleron stockholders will receive $180 in cash.

Key Points: 
  • Under the agreement terms, Acceleron stockholders will receive $180 in cash.
  • The investigation concerns whether the Acceleron board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Acceleron shares of common stock.
  • Nationally recognized, Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts' projections for future revenue growth.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia.

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer

Retrieved on: 
Friday, October 15, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, MRK, Royal commission, HIV disease progression rates, Death, Cancer, Risk, Radiation, RCC, Adult, European Medicines Agency, Advanced Therapy Medicinal Product, Committee, NYSE, Multimedia, PFS, Patient, Progression-free survival, European Union, European Commission, CHMP, EC, Committee for Medicinal Products for Human Use, Union, Pharmaceutical industry, LENVIMA® (lenvatinib); available as 10 mg and 4 mg capsules, Merck, Eisai, LENVIMA® (LENVATINIB); AVAILABLE AS 10 MG AND 4 MG CAPSULES, MERCK, EISAI

The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Key Points: 
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA, in combination with LENVIMA, is indicated for the first-line treatment of adult patients with advanced RCC.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older

Retrieved on: 
Friday, October 15, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Pneumococcal Disease, VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), Merck, PNEUMOCOCCAL DISEASE, VAXNEUVANCE (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE), MERCK

The CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances.

Key Points: 
  • The CHMP opinion was based on data from seven randomized, double-blind clinical studies evaluating VAXNEUVANCE in 7,438 individuals from a variety of adult populations and clinical circumstances.
  • Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
  • Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.
  • Please see U.S. Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance... and U.S.

COVID-19 Battering Healthcare Workers with 1 in 3 Battling Depression as Pandemic Rages, CulturIntel Study Finds

Retrieved on: 
Friday, October 15, 2021
PepsiCo, Merck, Prudential, Solution, CVS, Depression, Growth, Physician, Population, Hospital, HCPS, UnitedHealth Group, Johnson & Johnson, Multimedia, Grief, Light, Anger, American Express, Face, CEO, Emergency medical technician, Nursing, Behavior, Anxiety, Loss, Entrepreneurship, Kroger, Culture, COVID-19, Pharmaceutical industry, Medicine

DALLAS, Oct. 15, 2021 /PRNewswire/ --One in three healthcare workers are battling depression and more than 73% report feeling negative about their mental state because of the ongoing COVID-19 pandemic, according to Voices of Healthcare Heroes, a new study from CulturIntel released today.

Key Points: 
  • DALLAS, Oct. 15, 2021 /PRNewswire/ --One in three healthcare workers are battling depression and more than 73% report feeling negative about their mental state because of the ongoing COVID-19 pandemic, according to Voices of Healthcare Heroes, a new study from CulturIntel released today.
  • For example, the study reveals that physicians are experiencing 1.8 times more anger than the overall population, whereas overall healthcare workers are feeling 1.6 times more traumatized than the overall population.
  • The effect of the pandemic is heightened for healthcare workers as they are not seeing the light at the end of the tunnel and report facing too many challenges to move forward.
  • Despite these challenges, healthcare workers also report being three times more driven by purpose and camaraderie among their community.

International Federation of Fertility Societies Supports Individuals Globally with Fertility Plans During the Pandemic

Retrieved on: 
Thursday, October 14, 2021
World, Organization, Merck, World Health Organization, Social media, Federation, Physician, Reproductive health, Health care, Infertility, UN, Disease, WHO, News, Patient, List of international sports federations, Research, NSA, Human Fertility (British Fertility Society journal), COVID-19, Fur clothing

MOUNT ROYAL, N.J., Oct. 14, 2021 /PRNewswire-PRWeb/ -- The International Federation of Fertility Societies (IFFS) created a global infographic campaign aimed at providing support to individuals around the world who are looking to safely start or resume their fertility plans during the COVID-19 Pandemic.

Key Points: 
  • MOUNT ROYAL, N.J., Oct. 14, 2021 /PRNewswire-PRWeb/ -- The International Federation of Fertility Societies (IFFS) created a global infographic campaign aimed at providing support to individuals around the world who are looking to safely start or resume their fertility plans during the COVID-19 Pandemic.
  • IFFS saw the need for information that reaches a global audience, thus creating the infographics offered in a variety of languages.
  • The Federation will be monitoring and utilizing the hashtag #THINKINGOFHAVINGABABY and encourage like-minded organizations to do the same when sharing the materials.
  • IFFS represents over 65 UN country specific fertility societies that in the aggregate, encompass an estimated 50,000 physicians and reproduction medicine specialists worldwide including various healthcare professionals.

The Alliance for Advancing Health Online Invests $7M+ through the Vaccine Confidence Fund to Boost Vaccination Confidence through Social Media

Retrieved on: 
Thursday, October 14, 2021
Online, Vaccine Confidence Project, Organization, Facebook, VCF, Technology, Immunization, Sabin Vaccine Institute, Program, Health equity, Merck, Social media, Vaccine-preventable diseases, Tropical medicine, Natural language processing, Hygiene, Vaccination, Theory, Public health, GLOBE, London School of Hygiene & Tropical Medicine, Global Impact, Merck & Co., Vaccine hesitancy, Indigenous peoples, Communication, Polio, Research, Anthrax Vaccine Immunization Program, Risk, COVID-19, Pharmaceutical industry

VCF is the first flagship program of the Alliance for Advancing Health Online (AAHO).

Key Points: 
  • VCF is the first flagship program of the Alliance for Advancing Health Online (AAHO).
  • The AAHOs mission is to bring together members from the technology, health, global development and academic sectors to advance public understanding of how social media and other online platforms can be leveraged to increase vaccination confidence and vaccine uptake.
  • Supporting the public health efforts to increase vaccine confidence has been our top priority, said KX Jin, Facebooks Head of Health.
  • Finally, more than half of the grantees will be investigating the connection between social media (online) and vaccine uptake (offline) through vaccination bookings and/or actual vaccinations via health clinics.

New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Vall d'Hebron University Hospital, Electronics, Central nervous system, Inflammation, HIV disease progression rates, Multiple sclerosis, RMS, CNS, Blood, AFL, Rheumatoid arthritis, Disability, Lists of diseases, Neurology, Merck Millipore, Congress, Interferon beta-1a, Nerve, SLE, SEL, Health care, Neurodegeneration, Treatment, Phase, MS, Magnetic resonance imaging, Intelligence, Diarrhea, ALT, Macrophage, European Committee for Standardization, Common, Patient, Development, Science, Lupus, Degenerative disease, Urinary tract infection, Research, Gene editing, BTK, Health, Entrepreneurship, MRI, Data, MD, Hypoesthesia, Merck Serono, Pharmaceutical industry, Evobrutinib, Multiple Sclerosis, Merck, EVOBRUTINIB, MULTIPLE SCLEROSIS, MERCK

Evobrutinib reduced SEL volume compared to placebo in a dose-dependent manner with the highest effect with 75mg twice daily (p=0.047).

Key Points: 
  • Evobrutinib reduced SEL volume compared to placebo in a dose-dependent manner with the highest effect with 75mg twice daily (p=0.047).
  • In a subgroup analysis, the effect of evobrutinib on SEL volume was also especially apparent in patients with more advanced disease.
  • These results, combined with the reduction in Gd+ lesions reported previously, suggest that evobrutinib reduces both acute and chronic neuroinflammation that together lead to worsening disability.
  • These initial findings across NfL data combined with SEL data continue to show evobrutinibs potential benefit in disease progression.